Use of non-human primates (NHPs) continues to be necessary as part of the drug development process for various reasons, including current regulatory requirements and scientific justifications of human relevance, to ensure the safety of new pharmaceuticals in humans.
Watch Now
news-medical
Optimizing the receptor binding kinetics of new drugs can have significant benefits, ranging from improved duration of action to enhanced efficacy through the insurmountable antagonism of dynamic physiological systems.
Watch Now
Biopharma-asia
Large-scale Production of Biologics is susceptible to microbial contamination because many manufacturing steps occur under non-sterile conditions in aqueous systems at ambient temperature or 2-8 °C under substantially neutral pH conditions. Regardless of where in the Drug Substance (DS) manufacture (manufacture of the Active Pharmaceutical Ingredient), or Drug Product (DP) manufacture (manufacture of the Final Drug, e.g. formulated mAbs filled in vials or syringes) they occur, microbial contaminations can have a significant impact on product quality and patient safety.
Watch Now
IIdiopathic multicentric Castleman disease (iMCD) is a hematologic illness involving cytokine-induced lymphoproliferation, systemic inflammation, cytopenias and life-threatening multi-organ dysfunction.
Watch Now